Media headlines about Misonix (NASDAQ:MSON) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Misonix earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 48.6350868143057 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Separately, TheStreet downgraded Misonix from a “c-” rating to a “d” rating in a report on Friday.

Misonix (NASDAQ MSON) traded down $0.15 during midday trading on Tuesday, hitting $10.25. The stock had a trading volume of 19,000 shares, compared to its average volume of 9,348. The firm has a market cap of $96.00, a P/E ratio of -10.46 and a beta of 0.20. Misonix has a 12 month low of $7.05 and a 12 month high of $12.00.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Misonix (MSON) Stock Price” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at

About Misonix

Misonix, Inc designs, manufactures, develops and markets minimally invasive therapeutic ultrasonic medical devices. The Company’s products include BoneScalpel surgical system (BoneScalpel), SonaStar Surgical Aspirator (SonaStar), and SonicOne Wound Cleansing and Debridement System (SonicOne). These devices primarily serve the neurosurgery, orthopedic surgery, plastic surgery, wounds, burn and maxillo-facial clinical specialties.

Insider Buying and Selling by Quarter for Misonix (NASDAQ:MSON)

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with's FREE daily email newsletter.